BRAF Gene and Melanoma: Back to the Future
International Journal of Molecular Sciences Review BRAF Gene and Melanoma: Back to the Future Margaret Ottaviano 1,2,3,*,† , Emilio Francesco Giunta 4,† , Marianna Tortora 3 , Marcello Curvietto 5, Laura Attademo 2, Davide Bosso 2, Cinzia Cardalesi 2, Mario Rosanova 2, Pietro De Placido 1, Erica Pietroluongo 1 , Vittorio Riccio 1, Brigitta Mucci 1, Sara Parola 1, Maria Grazia Vitale 5, Giovannella Palmieri 3 , Bruno Daniele 2 , Ester Simeone 5 and on behalf of SCITO YOUTH ‡ 1 Department of Clinical Medicine and Surgery, Università Degli Studi di Napoli “Federico II”, 80131 Naples, Italy; pietrodep91@gmail.com (P.D.P.); erica.pietroluongo@gmail.com (E.P.); vittorioriccio1990@gmail.com (V.R.); brigitta.mucci@gmail.com (B.M.); saraparola3@gmail.com (S.P.) 2 Oncology Unit, Ospedale del Mare, 80147 Naples, Italy; laura.attademo@gmail.com (L.A.); davidebosso84@gmail.com (D.B.); cinzia.cardalesi@gmail.com (C.C.); rosanovamario@hotmail.com (M.R.); b.daniele@libero.it (B.D.) 3 CRCTR Coordinating Rare Tumors Reference Center of Campania Region, 80131 Naples, Italy; marian.tortora@gmail.com (M.T.); giovpalm@unina.it (G.P.) 4 Department of Precision Medicine, Università Degli Studi della Campania Luigi Vanvitelli, 80131 Naples, Italy; emiliofrancescogiunta@gmail.com 5 Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, 80131 Naples, Italy; curvietto.ma@gmail.com (M.C.); dott.mariagrazia.vitale@gmail.com (M.G.V.); ester.simeone@gmail.com (E.S.) * Correspondence: margaretottaviano@gmail.com † These authors contributed equally to this work. ‡ Membership of the SCITO YOUTH is provided in the Acknowledgments. Citation: Ottaviano, M.; Giunta, E.F.; Tortora, M.; Curvietto, M.; Attademo, Abstract: As widely acknowledged, 40–50% of all melanoma patients harbour an activating BRAF L.; Bosso, D.; Cardalesi, C.; Rosanova, mutation (mostly BRAF V600E).
[Show full text]